South Korea grants first approval worldwide to a stem cell therapy
This article was originally published in Scrip
Executive Summary
South Korea's FDA has granted the first commercial clearance in a regulated market to a therapy based on adult stem cells, awarding a marketing approval to FCB-Pharmicell's acute myocardial infarction (AMI) product Hearticellgram-AMI.